Arana, GW, Santos, AB, Laraia, MT et al (1995) Dexamethasone for the treatment of depression: a randomized, placebo-controlled, double-blind trial. American Journal of Psychiatry; 152: 265–7.
Arato, M, Banki, CM, Bissette, G et al (1989) Elevated CSF CRF in suicide victims. Biological Psychiatry; 25: 355–9.
Belanoff, JK, Rothschild, AJ, Cassidy, F et al (2002) An open label trial of C–1073 (mifepristone) for psychotic major depression. Biological Psychiatry; 52: 386–92.
Board, F, Wadeson, R, Persky, H (1957) Depressive affect and endocrine functions: blood levels of adrenal cortex and thyroid hormones in patients suffering from depressive reactions. Archives of Neurology and Psychiatry; 78: 612–20.
Broadbear, JH, Winger, G, Rivier, JE et al (2004) Corticotropin-releasing hormone antagonists, astressin B and antalarmin: differing profiles of activity in rhesus monkeys. Neuropsychopharmacology; 29: 1112–21.
Cardounel, A, Regelson, W, Kalimi, M (1999) Dehydroepiandrosterone protects hippocampal neurons against neurotoxin-induced cell death: mechanism of action. Proceedings of the Society for Experimental Biology and Medicine; 222: 145–9.
Cavanagh, JTO, van Beck, M, Muir, W et al (2002) Case–control study of neurocognitive function in euthymic patients with bipolar disorder: an association with mania. British Journal of Psychiatry; 180: 320–6.
Coryell, W, Young, E, Carroll, B (2006) Hyperactivity of the hypothalamic–pituitary–adrenal axis and mortality in major depressive disorder. Psychiatry Research; 142: 99–104.
Cowen, PJ (2002) Cortisol, serotonin and depression: all stressed out?
British Journal of Psychiatry; 180: 99–100.
DeBattista, C, Belanoff, J (2005) C-1073 (mifepristone) in the adjunctive treatment of Alzheimer's disease. Current Alzheimer Research; 2: 125–9.
Delva, NJ, Matthews, DR, Cowen, PJ (1996) Brain serotonin (5-HT) neuroendocrine function in patients taking cholesterol-lowering drugs. Biological Psychiatry; 39: 100–6.
Dinan, TG (1996) Serotonin and the regulation of hypothalamic–pituitary–adrenal axis function. Life Sciences; 58: 1683–94.
Dinan, TG, Scott, LV (2005) Anatomy of melancholia: focus on hypothalamic–pituitary–adrenal axis overactivity and the role of vasopressin. Journal of Anatomy; 207: 259–64.
Dorovini-Zis, K, Zis, AP (1987) Increased adrenal weight in victims of violent suicide. American Journal of Psychiatry; 144: 1214–5.
French, JA, Fite, JE, Jensen, H et al (2007) Treatment with CRH-1 antagonist antalarmin reduces behavioral and endocrine responses to social stressors in marmosets (Callithrix kuhlii). American Journal of Primatology; 69: 877–89.
Gallagher, P, Watson, S, Smith, MS et al (2005) Effects of adjunctive mifepristone (RU-486) administration on neurocognitive function and symptoms in schizophrenia. Biological Psychiatry; 57: 155–61.
Gallagher, P, Malik, N, Newham, J et al (2008) Antiglucocorticoid treatments for mood disorders. Cochrane Database of Systematic Reviews; issue 1: CD005168.
Gartside, SE, Leitch, MM, Young, AH (2003) Altered glucocorticoid rhythm attenuates the ability of a chronic SSRI to elevate forebrain 5-HT: implications for the treatment of depression. Neuropsychopharmacology; 28: 1572–8.
Glezer, I, Rivest, S (2004) Glucocorticoids: protectors of the brain during innate immune responses. Neuroscientist; 10: 538–52.
Goldstein, ET, Preskorn, SH (1989) Mania triggered by a steroid nasal spray in a patient with stable bipolar disorder. American Journal of Psychiatry; 146: 1076–7.
Harmer, CJ, Bhagwagar, Z, Shelley, N et al (2003) Contrasting effects of citalopram and reboxetine on waking salivary cortisol. Psychopharmacology; 167: 112–4.
Huffman, JC, Stern, TA (2007) Neuropsychiatric consequences of cardiovascular medications. Dialogues in Clinical Neurosciences; 9: 29–45.
Hunt, PJ, Gurnell, EM, Huppert, FA et al (2000) Improvement in mood and fatigue after dehydroepiandrosterone replacement in Addison's disease in a randomized, double blind trial. Journal of Clinical Endocrinology and Metabolism; 85: 4650–6.
Jahn, H, Schick, M, Kiefer, F et al (2004) Metyrapone as additive treatment in major depression: a double-blind and placebo-controlled trial. Archives of General Psychiatry; 61: 1235–44.
Karssen, AM, Meijer, OC, Berry, A et al (2005) Low doses of dexamethasone can produce a hypocorticosteroid state in the brain. Endocrinology; 146: 5587–95.
Kunugi, H, Ida, I, Owashi, T et al (2006) Assessment of the dexamethasone/CRH test as a state-dependent marker for hypothalamic–pituitary–adrenal (HPA) axis abnormalities in major depressive episode: a multicenter study. Neuropsychopharmacology; 31: 212–20.
Lester, D (1992) The dexamethasone suppression test as an indicator of suicide: a meta-analysis. Pharmacopsychiatry; 25: 265–70.
Lewis, LD, Cochrane, GM (1983) Psychosis in a child inhaling budesonide. Lancet; 2 (8350): 634.
Lopez, JF, Palkovits, M, Arato, M et al (1992) Localization and quantification of pro-opiomelanocortin mRNA and glucocorticoid receptor mRNA in pituitaries of suicide victims. Neuroendocrinology; 56: 491–501.
Lupien, SJ, McEwen, BS (1997) The acute effects of corticosteroids on cognition: integration of animal and human model studies. Brain Research Reviews; 24: 1–27.
Man, MS, Young, AH, McAllister-Williams, RH (2002) Corticosterone modulation of somatodendritic 5-HT1A receptor function in mice. Journal of Psychopharmacology; 16: 245–52.
McQuade, R, Young, AH (2000) Future therapeutic targets in mood disorders: the glucocorticoid receptor. British Journal of Psychiatry; 177: 390–5.
Mendelson, SD, McEwen, BS (1992) Quantitative autoradiographic analyses of the time course and reversibility of corticosterone-induced decreases in binding at 5-HT1A receptors in rat forebrain. Neuroendocrinology; 56: 881–8.
Meyboom, RH, De Graaf-Breederveld, N (1988) Budesonide and psychic side effects. Annals of Internal Medicine; 109: 683.
Murphy, BE, Filipini, D, Ghadirian, AM (1993) Possible use of glucocorticoid receptor antagonists in the treatment of major depression: preliminary results using RU 486. Journal of Psychiatry and Neuroscience; 18: 209–13.
Murphy, BE (1997) Antiglucocorticoid therapies in major depression: a review. Psychoneuroendocrinology; 22 (suppl 1): s125–32.
Nelson, JC, Davis, JM (1997) DST studies in psychotic depression: a meta-analysis. American Journal of Psychiatry; 154: 1497–503.
Nemeroff, CB, Owens, MJ, Bissette, G et al (1988) Reduced corticotropin releasing factor binding sites in the frontal cortex of suicide victims. Archives of General Psychiatry; 45: 577–9.
Ormiston, T, Wolkowitz, OM, Reus, VI et al (2004) Hormonal changes with cholesterol reduction: a double-blind pilot study. Journal of Clinical Pharmacy and Therapeutics; 29: 71–3.
Pfennig, A, Kunzel, HE, Kern, N et al (2005) Hypothalamus–pituitary–adrenal system regulation and suicidal behavior in depression. Biological Psychiatry; 57: 336–42.
Phelan, MC (1989) Beclomethasone mania. British Journal of Psychiatry; 155: 871–2.
Porter, RJ, Gallagher, P, Watson, S et al (2004) Corticosteroidserotonin interactions in depression: a review of the human evidence. Psychopharmacology; 173: 1–17.
Raadsheer, FC, van Heerikhuize, JJ, Lucassen, PJ et al (1995) Corticotropin-releasing hormone mRNA levels in the paraventricular nucleus of patients with Alzheimer's disease and depression. American Journal of Psychiatry; 152: 1372–6.
Ravaris, CL, Sateia, MJ, Beroza, KW et al (1988) Effect of ketoconazole on a hypophysectomized, hypercortisolemic, psychotically depressed woman. Archives of General Psychiatry; 45: 966–7.
Sapolsky, RM, Krey, LC, McEwen, BS (1986) The neuroendocrinology of stress and aging: the glucocorticoid cascade hypothesis. Endocrine Reviews; 7: 284–301.
Thompson, JM, Gallagher, P, Hughes, JH et al (2005) Neurocognitive impairment in euthymic patients with bipolar affective disorder. British Journal of Psychiatry; 186: 32–40.
Walder, DJ, Walker, EF, Lewine, RJ (2000) Cognitive functioning, cortisol release, and symptom severity in patients with schizophrenia. Biological Psychiatry; 48: 1121–32.
Watson, S, Gallagher, P, Ritchie, JC et al (2004) Hypothalamic–pituitary–adrenal axis function in patients with bipolar disorder. British Journal of Psychiatry; 184: 496–502.
Watson, S, Gallagher, P, Ferrier, IN et al (2006) Post-dexamethasone arginine vasopressin levels in patients with severe mood disorders. Journal of Psychiatric Research; 40: 353–9.
Webster, MJ, Knable, MB, O'Grady, J et al (2002) Regional specificity of brain glucocorticoid receptor mRNA alterations in subjects with schizophrenia and mood disorders. Molecular Psychiatry; 7: 985–94.
Westrin, A, Nimeus, A (2003) The dexamethasone suppression test and CSF-5-HIAA in relation to suicidality and depression in suicide attempters. European Psychiatry; 18: 166–71.
Wolkowitz, OM, Reus, VI, Weingartner, H et al (1990) Cognitive effects of corticosteroids. American Journal of Psychiatry; 147: 1297–303.
Wolkowitz, OM, Reus, VI, Keebler, A et al (1999) Double-blind treatment of major depression with dehydroepiandrosterone. American Journal of Psychiatry; 156: 646–9.
Yehuda, R (2001) Biology of posttraumatic stress disorder. Journal of Clinical Psychiatry; 62 (suppl 17): 41–6.
Yehuda, R (2006) Advances in understanding neuroendocrine alterations in PTSD and their therapeutic implications. Annals of the New York Academy of Sciences; 1071: 137–66.
Young, AH (1994a) Glucocorticoids, serotonin and mood. British Journal of Psychiatry; 165: 271–2.
Young, AH, Sharpley, AL, Campling, GM et al (1994b) Effects of hydrocortisone on brain 5-HT function and sleep. Journal of Affective Disorders; 32: 139–46.
Young, AH, Sahakian, BJ, Robbins, TW et al (1999) The effects of chronic administration of hydrocortisone on cognitive function in normal male volunteers. Psychopharmacology; 145: 260–66.
Young, AH, Gallagher, P, Porter, RJ (2002) Elevation of the cortisol–dehydroepiandrosterone ratio in drug-free depressed patients. American Journal of Psychiatry; 159: 1237–9.
Young, AH, Gallagher, P, Watson, S et al (2004) Improvements in neurocognitive function and mood following adjunctive treatment with mifepristone (RU-486) in bipolar disorder. Neuropsychopharmacology; 29: 1538–45.
Young, EA, Breslau, N (2004a) Saliva cortisol in posttraumatic stress disorder: a community epidemiologic study. Biological Psychiatry; 56: 205–9.
Young, EA, Altemus, M, Lopez, JF et al (2004b) HPA axis activation in major depression and response to fluoxetine: a pilot study. Psychoneuroendocrinology; 29: 1198–204.
Zhou, DF, Shen, YC, Shu, LN, et al (1987) Dexamethasone suppression test and urinary MHPG X SO4 determination in depressive disorders. Biological psychiatry; 22: 883–91.
Zobel, AW, Nickel, T, Sonntag, A et al (2001) Cortisol response in the combined dexamethasone/CRH test as predictor of relapse in patients with remitted depression: a prospective study. Journal of Psychiatric Research; 35: 83–94.